How to Buy Esperion Therapeutics Stock
Esperion Therapeutics Inc
Esperion Therapeutics, Inc. , a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
Esperion Therapeutics stock last closed at $0.85, down 10.32% from the previous day, and has decreased 55.39% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.01 percentage points. Esperion Therapeutics stock is currently +4.03% from its 52-week low of $0.82, and -78.38% from its 52-week high of $3.94.
At the moment, there are 197.85M shares of ESPR outstanding. The market cap of ESPR is $168.57M. In the past 24 hours, 5.87M ESPR shares were traded.
How to Buy Esperion Therapeutics Stock
Not sure how to invest in Esperion Therapeutics stock? Here's how.
- Figure out where to buy Esperion Therapeutics stock: You need to pick a stock brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you figure out where to buy Esperion Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Put funds into your investment account: Pick your payment method and add your info.
- Evaluate Esperion Therapeutics stock: The Esperion Therapeutics ticker symbol is ESPR. Is Esperion Therapeutics stock a good investment? Should you buy shares of ESPR? How do ESPR's underlying business fundamentals look? Do top analysts think Esperion Therapeutics is a good buy? Why has ESPR's stock price moved recently? (Hint: Our stock research tools can help you evaluate if ESPR is a good stock to buy).
- Make your ESPR buy order: Decide if you will purchase ESPR shares at the current market price or use a limit order to buy ESPR shares at a specific price.
- Get updates on your ESPR position: Create a watchlist to monitor your new investment in Esperion Therapeutics shares.
Step 1: Figure out where to buy Esperion Therapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy ESPR shares.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world financial markets: From Tech to Healthcare, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community of more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen the best brokerage, it's time to fill out some personal information so you can buy ESPR today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to start a new trading account.
- Send your application by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've opened your account on the highest rated app to buy and sell stocks, you need to deposit funds:
Check out the video below if you need help transferring funds into your investment account.
Step 4: Evaluate Esperion Therapeutics stock
Once you have chosen the best place to buy Esperion Therapeutics stock, it's important to research their stock before you invest, so you can comprehend the risk as well as the opportunity.
Overview of key ESPR info
Esperion Therapeutics Overview
WallStreetZen was created to help everyday investors do more in-depth fundamental analysis.
You can view all of the due diligence checks on ESPR's stock page.
What is the fair value of ESPR stock?
You can use many financial metrics, analyses, models, and charts to gauge ESPR's true value.
You can do additional valuation analysis on ESPR's stock here.
ESPR Financials at a glance
Passed Health Checks:
- ESPR profit margin has gone up from -179.9% to -15.6% in the past year.
- ESPR has $144.76M in cash and short term investments. This is sufficient to cover its annual cash burn of $23.97M.
- ESPR has cash burn of 23971000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the ESPR balance sheet.
Failed Health Checks:
- ESPR debt to equity ratio of -1.88 is negative.
- Total ESPR debt is still negative.
- There are more long-term liabilities than short-term assets on the ESPR balance sheet.
Is Esperion Therapeutics stock a Buy, Hold, or Sell, according to analysts?
Out of 6 Equities analysts who track ESPR, the consensus analyst rating on Esperion Therapeutics is a Buy
Please note that analyst ratings are not recommendations, nor are they investment advice.
Most Recent ESPR Analyst Recommendations
Kristen Kluska, a top 3% analyst from Cantor Fitzgerald initiates coverage on ESPR with a strong buy rating and announces their ESPR price target of $8.00, on Dec 17, 2024.
You can dive deeper into what analysts are projecting on the Esperion Therapeutics stock forecast page.
Metrics for Advanced ESPR Traders
ESPR Growth Numbers
Last year, ESPR revenue was $332.31M. Over the last 5 year, ESPR's revenue has increased by 17.5% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 7.89%.
Learn more about ESPR's earnings and revenue performance here.
What are ESPR executives and large shareholders up to?
Over the past 12 months, insiders at ESPR have sold more shares than they have bought.
Benjamin Halladay, Chief Financial Officer of ESPR, was the latest ESPR insider to sell. They sold $7.71 worth of ESPR stock on Apr 17, 2025.
Research more about who owns ESPR stock here.
Can I get consistent income from ESPR stock?
No, Esperion Therapeutics doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your ESPR buy order
There are two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly the easiest way to buy. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a specific price limit, place a limit order.
Click the Open Trade button and eToro will execute your order.
If you need more help investing in stocks on eToro, watch the helpful video below:
Step 6: Get updates on your ESPR position
Now that you own some ESPR shares, you'll want to stay up-to-date on your new investment.
Make a watchlist to track the latest developments regarding your ESPR stock.
ESPR Feed
How to Buy Stock in Esperion Therapeutics
To summarize, here are the 6 steps to buy stock in Esperion Therapeutics:
- Figure out where to buy Esperion Therapeutics stock
- Open your brokerage account
- Put funds into your investment account
- Evaluate Esperion Therapeutics stock
- Make your ESPR buy order
- Get updates on your ESPR position
If you require a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep an eye on your investment in Esperion Therapeutics, add ESPR to your watchlist below.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.